# Dynamk Capital

> Dynamk Capital is a VC fund in New York backing Biotechnology and Medical. See 20 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 20
- Last investment: Sep 2023
- Lead investor: 75%
- Fund size: $57M
- Last fund: Sep 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/11288729/
- X (Twitter): https://twitter.com/DynamkVC
- Website: http://www.dynamk.vc

Dynamk Capital is a VC fund in New York focused on Biotechnology and Medical. Dynamk Capital invests in innovative tools and technologies that are critical for the discovery, development and production of life-saving therapies.We partner with life science visionaries whose market-defining ideas are shaping the future of how therapeutics are being developed, increasing access for patients, and reducing costs.

## Contacts

5 contacts available for Dynamk Capital. Shizune tracks 4 team members at Dynamk Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/dynamk-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 10 | 50% |
| Medical | 6 | 30% |
| Health Care | 4 | 20% |
| Life Science | 4 | 20% |
| Therapeutics | 2 | 10% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 9 | 45% |
| Seed | 4 | 20% |
| Series B | 2 | 10% |
| Funding Round | 2 | 10% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 45% |
| Canada | 1 | 5% |
| Norway | 1 | 5% |
| Switzerland | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Daniella Kranjac | Founding Partner | 9 | https://shizune.co/investors/profile/daniella-kranjac |
| Reinhard Vogt | Managing Director | 2 | https://shizune.co/investors/profile/reinhard-vogt |
| Gustavo Mahler | Venture Partner | 9 | https://shizune.co/investors/profile/gustavo-mahler |
| Sebastien Latapie | Principal | 2 | https://shizune.co/investors/profile/sebastien-latapie |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CellFE | CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells. | $22M | Series A | Sep 27, 2023 |  |
| Lucid Scientific | Lucid Scientific is a biotechnology tools company working to accelerate drug discovery and basic biological research by providing systems for real-time cellular analysis. It has invented an innovative new system for monitoring cell culture experiments. The company’s flagship technology, called RESIPHER, provides continuous and non-invasivemeasurement of oxygen consumption in a cell culture plate, then streams this information to a convenient web app. | $7M | Series A | Sep 05, 2023 |  |
| Vernal Biosciences | Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $20M | Series A | Jun 27, 2023 |  |
| Vernal Biosciences | Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $21M |  | Jun 02, 2022 |  |
| Vernal Biosciences | Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $21M | Series A | Jun 02, 2022 |  |
| Bionter | Bionter operates as a company with the purpose of revolutionizing analytical testing for the benefit of people's health. | $3M | Seed | Apr 27, 2022 |  |
| Xcell Biosciences | Xcell Biosciences is a San Francisco-based life science start-up company that is developing novel and disruptive systems for cell therapy development and production. Their proprietary technology enables fine control of primary cell phenotype and function, enabling an entirely new capability for optimizing efficacy and persistence of immune celltherapies. | $27.5M | Series B | Jan 19, 2022 |  |
| Curi Bio | Curi Bio is a biotechnology company that focuses on advancing drug discovery and development through innovative approaches involving human stem cells, systems biology, and data analytics. The company's primary goal is to accelerate the process of identifying and developing new medicines.Curi Bio's platform revolves around the use ofhuman stem cells, which have the potential to be differentiated into various cell types, replicating the behavior of different tissues and organs. This allows researchers to create more accurate and relevant models for studying disease mechanisms and testing potential drug candidates.NanoSurface Biomedical Is Now Curi Bio. | $10M | Series A | Dec 29, 2021 |  |
| Virica Biotech | Virica Biotech is a biotechnology company that addresses the unmet needs in production and development to positively change human health. Its Viral Sensitizer technology consists of a library of over one hundred small molecules that can safely overcome the natural immunological defenses in the human and animal body that suppress effective viralmedicines. |  | Series A | Oct 04, 2021 |  |
| Envisagenics | Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused bymutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered.Their breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. | $19.2M | Series A | Sep 29, 2021 |  |

10 of 20 investments shown.

## Co-investors
- [Charles River Laboratories International](https://shizune.co/investors/profile/charles-river-laboratories-international) — VC Fund, 3 deals together
- [Third Kind Venture Capital](https://shizune.co/investors/profile/high-line-venture-partners) — VC Fund, 3 deals together
- [Alloy Therapeutics](https://shizune.co/investors/profile/alloy-therapeutics) — VC Fund, 2 deals together
- [Ampersand Capital Partners](https://shizune.co/investors/profile/ampersand-ventures) — VC Fund, 2 deals together
- [Cota Capital](https://shizune.co/investors/profile/cota-capital) — VC Fund, 2 deals together
- [Elm Street Ventures](https://shizune.co/investors/profile/elm-street-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Investinor](https://shizune.co/investors/profile/investinor) — VC Fund
- [Skyfall Ventures](https://shizune.co/investors/profile/skyfall-ventures) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Norway](https://shizune.co/investors/biotechnology-investors-norway)
- [Biotechnology VC Funds in Norway](https://shizune.co/investors/biotechnology-vc-funds-norway)
- [Health Care VC Funds in Norway](https://shizune.co/investors/health-care-vc-funds-norway)
- [Biotech Investors in Norway](https://shizune.co/investors/biotech-investors-norway)
- [Biotech VC Funds in Norway](https://shizune.co/investors/biotech-vc-funds-norway)
- [Life Science Investors in Norway](https://shizune.co/investors/life-science-investors-norway)

## FAQ

### What does Dynamk Capital invest in?

Dynamk Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Dynamk Capital?

Public channels for Dynamk Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Dynamk Capital?

The team at Dynamk Capital includes Daniella Kranjac (Founding Partner), Reinhard Vogt (Managing Director) and Gustavo Mahler (Venture Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co